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Abstract 
Nitisinone is a reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase and an 
active substance in the orphan drug used for the treatment of hereditary tyrosinemia type I, 
a rare genetic disease caused by mutations in the gene for the enzyme fumarylacetoacetase. 
The aim of our study was to develop a simple and accurate RP–HPLC method with UV 
detection for routine determination of nitisinone in commercially available pharmaceutical 
forms. The chromatographic separation was achieved on a reversed-phase column 
Purospher STAR® RP–8 end–capped (150 x 4.6 mm i.d., particle size 5 μm), with a mobile 
phase consisted of a mixture of acetonitrile and water acidified with o-phosphoric acid with 
pH adjusted to 3.0, 65:35 (V/V), filtered through 0.45μm nylon filter. The flow rate was 
kept at 1 mL/min. A diode array detector measured the UV absorbance at 272 nm. The 
injection volume was 10 μL. The method was validated by a determination of system 
suitability, specificity, linearity, range, accuracy, precision, detection limit and quantitation 
limit. Then, the method was applied for determination of  nitisinon in commercially 
available capsules. The proposed RP-HPLC method allows a simple, accurate, precise and 
rapid determination of nitisinone in pharmaceuticals. The advantages of the method include 
simple sample treatment, good precision (RSD less than 2%) and high recovery (greater 
than 99%). The method could be recommended for routine analysis in quality control 
laboratories, in stability studies as well as for the evaluation of potentially counterfeit 
capsules containing nitisinone. 
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Introduction 
 
Hereditary tyrosinaemia type 1 (HT-1) is a rare genetic disease caused by mutations 
in the gene for the enzyme fumarylacetoacetase. It usually presents with liver failure 
however it can be manifest as chronic liver disease. It is considered that there is a 
significant lifetime risk of developing hepatocellular carcinoma. Before the development of 
liver transplantation, most of the patients died in childhood (McKiernan, 2006). 
Nitisinone (NTBC) is a reversible inhibitor of 4-hydroxyphenylpyruvate 
dioxygenase and an active substance in the orphan drug used for the treatment of hereditary 
tyrosinemia type I (De Laetet al., 2013). The chemical name of nitisinone is 2-(2-nitro-4-
trifluoromethyl benzoyl)-1,3-cyclohexanedione (Fig. 1), with empirical formula 
C14H10F3NO5, and molecular weight is 329.228 g/mol. 
Nitisinone appears as off-white to yellowish non-hygroscopic fine crystalline 
powder. It is practically insoluble in water, freely soluble in dichloromethane, sparingly 
soluble in ethyl alcohol. Furthermore, NTBC is slightly soluble in isopropyl alcohol and 
70% aqueous isopropyl alcohol and in pH 6.8 phosphate buffer, very slightly soluble in pH 
4.5 acetate buffer and practically insoluble at pH 1.1. Solubility in acidified aqueous media 
depends on the acid counter ion. Solubility increases with increasing Ph. Its pKa was found 
to be around 10. NTBC is achiral and does not show polymorphism (Aktuglu-Zeybek and 
Zubarioglu, 2017). 
 
Fig. 1 
 
The innovator product containing NTBC active substance (Orfadin®2 mg, 5 mg, 10 
mg and 20 mg hard capsules), was approved for treatment of tyrosinemia, by the FDA and 
the EMA, on 21.02.2002 and 21.02.2005, respectively. In the treatment of hereditary 
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tyrosinemia Type I, NTBC, a 4-hydroxyphenylpyruvate dioxygenase inhibitor, is 
recommended to be used in combination with limiting dietary tyrosine and phenylalanine 
intake (Lock et al., 2014). 
NTBC has transformed the natural history of tyrosinaemia. The studies showed that 
liver failure is controlled in 90% of patients, those with chronic liver disease improve and 
nonhepatic manifestations are abolished. Furthermore, NTBCis well tolerated and has few 
adverse effects other than a predictable rise in plasma tyrosine levels (McKiernan, 2006). 
There are only a small number of articles published on the determination of NTBC 
in pharmaceuticals and biological samples (Bielenstein et al., 1999; Hallet al., 2001). 
Capillary electrophoresis (Cansever et al., 2010) and LC‑MS/MS methods (Davit-Spraul et 
al., 2012; Herebian et al., 2009; La Marca et al., 2011; Prieto et al., 2011; Sander et al., 
2011) have been reported for the determination of NTBC in biological fluids. Recently, 
Souri et al. (2015) developed a stability–indicating HPLC method for the determination of 
NTBC in capsules. Additionally, it should be noted that there is still no pharmacopeial 
monograph for nitisinone.  
Therefore, our aim was to develop a simple and accurate RP–HPLC method with 
UV detection for determination of nitisinone in pharmaceuticals, without long steps of 
sample preparation and with adequate sensitivity for routine analysis in quality control 
laboratories, for stability studies, as well as for the evaluation of potentially counterfeit 
NTBC products. 
 
Materials and methods 
Chemical and reagents 
Commercially available samples, hard capsules containing 5 mg or 10 mg nitisinone 
were used in this study. NTBC standard substance was provided by Ulkar Kimya Sanayii 
ve Ticaret A.Ş. (Turkey). HPLC-grade acetonitrile was purchased from Merck (Darmstadt, 
Germany). Double-distilled water was used to prepare mobile phase solutions. 
 
HPLC instrumentation and conditions 
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HPLC analyses were performed using an Agilent Technologies chromatographic 
system (Hewlett Packard, Avondale, USA) consisting of a Model 1200 Series SL pump 
with a Model Agilent series G-1315C DAD detector and a Model Agilent 1200 series G-
1329B ALS auto sampler. Data analyses were done using Agilent Technologies HPLC 
1100 software. The chromatographic separation was achieved on a reversed-phase column 
Purospher STAR® RP–8 end–capped (150 x 4.6 mm i.d., particle size 5 μm), at the 
temperature of 25 °C. The mobile phase consisted of a mixture of acetonitrile and water 
acidified with o-phosphoric acid (pH 3.0), 65:35 (V/V), filtered through 0.45 μm nylon 
filter. The flow rate was kept at 1 mL/min. Wavelength was selected by scanning a standard 
solution of NTBC over 200-400 nm using Model Lambda 12 (Perkin Elmer) UV-visible 
spectrophotometer. The wavelength of 272 nm was chosen for detection of NTBC. The 
injection volume was 10 μL. 
 
Preparation of solutions 
A stock solution of NTBC was prepared by dissolving about 1.0 mg of the NTBC 
standard substance (accurately weighed on the analytical balance with readability to 0.01 
mg (5 decimal places)) in acetonitrile and diluting with the same solvent up to 10 mL. 
Working standard solution (target concentration of 0.1 mg/mL) was prepared by dilution of 
the stock standard solution with the same solvent.  
For evaluation of linearity, seven aliquots of the stock solution were appropriately 
diluted with the same solvent to obtain solutions of NTBC in concentration range of 
0.00844 – 0.422 mg/mL. 
Twenty capsules were weighed accurately on the analytical balance with readability 
to 0.01 mg and the net content of each capsule was calculated. Capsule powder equivalent 
to 10 mg NTBC was accurately weighed and transferred to a 100 mL volumetric flask with 
addition of about 70 mL acetonitrile. The mixture was sonicated in an ultrasonic bath for 15 
min. and volume was made up to the mark with the same solvent (target concentration of 
0.1 mg/mL NTBC). 
All solvents and solutions for HPLC analysis were filtered through a membrane 
filter (0.45 μm pore size) and vacuum degassed before use. 
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Method validation  
The proposed method was validated according to the ICH Harmonized Tripartite 
Guideline; Validation of Analytical Procedures: Text and Methodology Q2(R1) (ICH, 
2005). The parameters used to validate the analytical method were system suitability, 
specificity, linearity, range, accuracy, precision, detection limit (DL) and quantitation limit 
(QL). 
 
System suitability 
System suitability testing is considered as an integral part of the chromatographic 
method validation procedure and is regularly performed in order to check on-going 
performance of the chromatographic system. We estimated the system repeatability by 6 
consecutive injections of standard solution at 100% of the test concentration (0.1 mg/mL 
NTBC). The system suitability parameters were calculated as described in the United States 
Pharmacopoeia (General Chapter <1225>; <621>). As acceptance criteria we used the 
limits recommended in the FDA guideline on "Validation of Chromatographic Methods" 
(1994). 
 
Specificity  
Specificity is defined as the ability of the analytical procedure to assess 
unequivocally the analyte in the presence of components which may be expected to be 
present (impurities, degradants, matrix, etc.). In the case of assay (determination of content 
or potency), specificity is also the ability of the analytical procedure to provide an exact 
result which allows an accurate statement on the content or potency of the analyte in a 
sample (ICH, 2005). The specificity of the proposed method was demonstrated by spiking 
the capsule formulations with known quantities of NTBC standard, then checking for 
interference with the placebo.  
 
Linearity and range 
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For linearity evaluation, a calibration curve was obtained at 7 concentration levels 
of NTBC standard solutions (0.00844 – 0.422 mg/mL). The solutions (10 μL) were injected 
in triplicate into a chromatographic system using the proposed chromatographic conditions. 
Then, the peak area and concentrations were subjected to a least square regression analysis 
to calculate calibration equation and determination coefficient. 
 
Precision  
The precision of the proposed analytical procedure (intra-assay precision) was 
assessed using six determinations of sample solutions at 100% of the test concentration (0.1 
mg/mL NTBC) on the same day, by the same analyst and using the same equipment. The 
intermediate precision of the analytical procedure was assessed analyzing the same sample 
solutions on three consecutive days. The precision was expressed as the relative standard 
deviation of series of measurements.  
 
Detection limit and quantitation Limit 
Detection limit (DL) and quantitation limit (QL) of the proposed RP-HPLC method 
were determined by injecting low concentrations of the standard solutions (0.00844 - 
0.0422 mg/mL). We calculated DL and QL according to ICH guidelines (ICH, 2005) 
applying a signal-to-noise ratio approach. We measured signals from samples with known 
low concentrations of NTBC with those of blank samples and then we established the 
minimum concentration at which NTBC can be reliably detected. A signal-to-noise ratio 
between 3.3:1 was considered acceptable for estimation of the detection limit, while a 
typical signal-to-noise ratio for quantitation limit was 10:1. 
 
Accuracy 
To study the accuracy of the proposed analytical method, recovery tests were 
conducted using the standard addition method. Hence, known amounts of NTBC standard 
substance were added to capsules and the resulting mixtures were analyzed by the proposed 
methods. We spiked placebo samples with NTBC standard solution at three concentration 
levels (0.08262 - 0.12141 mg/mL). The percent of recovery was calculated as follows: 
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Recovery (%) = [[Cv – Cu]/Ca] x 100 
where Cv is the total amount of NTBC measured after standard addition, Cu the 
amount of NTBC in the drug formulation, and Ca the amount of NTBC added to the 
formulation. 
 
Results and discussion 
Method development 
During the method development, we applied isocratic HPLC system with safe 
mobile phase (not highly saline, pH more than 2.5, and acceptable flow rate). A variety of 
mobile phases and different columns were investigated in the development of a HPLC 
method for analysis of NTBC. These included: acetonitrile – water, 50:50 (V/V), 
acetonitrile – water, 70:30 (V/V), acetonitrile – water acidified with o-phosphoric acid with 
pH adjusted to 3.0, 65:35 (V/V) and different columns (RP-C8, and RP-C18) from different 
manufacturers with different lengths (25.0, 15.0, 12.5, and 10.0 cm) and constant internal 
diameter of 4.6 mm. The suitability of the mobile phase was decided on a basis of the 
sensitivity of the assay, ease of preparation, and use of readily available cost-effective 
solvents. Thus, the mobile phase consisted of a mixture of acetonitrile and water acidified 
with o-phosphoric acid with pH adjusted to 3.0, 65:35 (V/V) and the reversed-phase column 
Purospher STAR® RP–8 end–capped (150 x 4.6 mm i.d., particle size 5 μm), was found 
optimal for isocratic determination of NTBC in pharmaceuticals. The wavelength was 
selected by scanning the standard solution of NTBC over 200-400 nm and the wavelength 
of 272 nm was chosen for detection of NTBC (Fig. 2). 
 
Fig. 2 
 
NTBC was identified based on the retention time as compared with the NTBC 
standard. Furthermore, the identification NTBC was confirmed by adding standard to 
sample solution prior to analysis, which resulted in an increased peak area proportionally to 
the added amount of NTBC. The average retention time of the NTBC was approximately 
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4.03 min at a flow rate of 1 mL/min. The NTBC was determined in a short time as a sharp 
single peak. About 10 min was required for each analysis. No interference from excipients 
and potential degradation products was observed (Fig. 3). 
 
Fig. 3 
 
Method validation 
System suitability - The results of system suitability test (Table 1) were found within the 
acceptable range proving that the chromatographic system was suitable for NTBC 
determination. Acceptable peak symmetry (tailing factor) and retention time were observed 
without any interference from capsule excipients or degradation products. System 
suitability parameters were obtained from six replicate injections. 
 
Table 1 
 
Specificity - In the specificity study, standard solution of NTBC and sample solutions 
containing NTBC were injected and a single peak was obtained for NTBC, which indicates 
that there was no interference from the excipients used or from the mobile phase. 
Representative chromatograms of a NTBC standard solution, sample solutions and a blank 
solution are presented in Fig. 3 (a, b, c, d). 
 
Linearity and range - In the present study, linearity was studied in the concentration range 
of 0.00844 – 0.422 mg/mL NTBC and the following regression equation was found by 
plotting the peak area (y) expressed in mAU versus the NTBC concentration (x) expressed 
in mg/mL: y = 15165x – 23.019 (r2 = 0.9999). The determination coefficient (r2) 
demonstrates the excellent relationship between the peak area and the concentration of 
NTBC. The regression lines were not significantly different from a curve passing through 
the origin y = a x. (P-value of the slope > 0.05). (Table 2). 
 
Table 2 
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Precision and accuracy - The variation in the results obtained within a day (RSD = 0.29%, 
and RSD = 0.50%, for Nitisinone 5 mg capsule, and 10 mg capsule, respectively) and day 
to day variations (RSD = 0.43%) for NTBC determination was very low (≤ 2%), thus 
confirming the precision of the method. The statistical data is shown in Table 3. 
 
Table 3 
 
The average recovery of the added amounts of NTBC at three concentration levels 
was 99.22% ± 0.86% (n = 9). Mean recovery (Table 4) was between 98.42% and 100.76% 
indicating that the proposed method was sufficiently accurate for the determination of 
NTBC in pharmaceutical formulation. 
 
Table 4 
 
Detection limit and quantitation limit - The limit of detection (DL) and limit of quantitation 
(QL) were 0.0486 µg/mL and 0.147 µg/mL, respectively. The proposed RP-HPLC method 
was demonstrated to be sensitive for performing the determination of NTBC during the 
product release and throughout the shelf life of pharmaceuticals containing nitisinone active 
substance. 
 
Method applications 
The validated method was applied for determination of NTBC in commercially 
available Nitisinone 5 mg and 10 mg hard capsules. Fig. 2 illustrates typical HPLC 
chromatograms obtained from a standard solution, Nitisinone 5 mg and 10 mg hard 
capsules sample solutions, and blank solution, respectively. The results of the assay (n = 20 
capsules) undertaken yielded 106.63% (RSD = 0.29%), and 107.33 % (RSD = 0.50%) of 
label claim for NTBC in Nitisinone 5 mg capsule, and 10 mg capsule, respectively. The 
average retention time of nitisinone was approximately 4.03 min. The results indicate that 
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the method is specific for the analysis of nitisinone without interference from the excipients 
used to formulate and produce these capsules. 
 
Conclusion 
 
The proposed RP-HPLC method allows a simple, accurate, precise and rapid 
determination of nitisinone API in pharmaceuticals. The advantages of the method include 
simple sample treatment with sonication of small amounts of sample at ambient 
temperature, good precision (RSD < 2%) and high recovery (greater than 99%). 
Additionally, simple preparation reduces the laboratory expenses, while retaining enough 
sensitivity for determination of NTBC in commercially available pharmaceutical 
preparations. The proposed method could be applied for routine analysis in quality control 
laboratories, in stability studies as well as for the evaluation of potentially counterfeit 
Nitisinone capsules. 
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Резиме 
 
Едноставен изократски реверзно-фазен HPLC метод за определување на 
нитисинон во фармацевтски препарати 
  
Зана Мустафа1*, Зорица Арсова-Сарафиновска1, Маја Шишовска1,  
Александра Грозданова2 
 
1Институт за јавно здравје на Република Северна Македонија, ул. 50 Дивизија бр. 6, 
1000 Скопје, Република Северна Македонија 
2 Институт за фармацевтска хемија, Фармацевтски факултет, 
Универзитет „Св Кирил и Методиј“, Мајка Тереза 47, 1000 Скопје, 
Република Северна Македонија 
 
Клучни зборови: нитисон; течна хроматографија под висок притисок; валидација на 
метод; наследна тирозинемија тип 1 
 
Нитисинон е реверзибилен инхибитор на ензимот 4-хидроксифенил-пируват-
диоксигеназа и активна супстанција во лекот за ретки болести наменет за третман на 
наследна тирозинемија тип I, ретка болест предизвикана од мутации на генот за 
ензимот фумарилацетоацет хидролаза. Цел на нашата студија беше да се развие 
едноставен и точен реверзно-фазен HPLC метод за рутинско определување на 
нитисинон во комерцијално достапни дозирани фармацевтски форми.  
Хроматографското раздвојување беше постигнато со употреба на Purospher STAR® 
RP-8  реверзно-фазна колона (150  x 4.6 mm I.D., со големина на честички 5 μm), со 
мобилна фаза составена од ацетонитрил и вода (закиселена со о-фосфорна киселина 
до pH 3,0), во однос 65:35 (V/V),  филтрирана преку најлонски филтер со големина на 
пори 0,45 μm. Елуирањето го изведовме со проток од 1 mL/min. Волуменот на 
инјектирање беше 10 μL. Апсорпцијата на примерокот ја измеривме со DAD детектор 
на бранова должина од 272 nm.  
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Методот го валидиравме со утврдување на параметрите: соодветност на 
системот, специфичност, линеарност, опсег, точност, прецизност, граница на 
детекција и граница на определување. Потоа, ја определивме содржината на 
нитинонон во комерцијално достапни  капсули. Методот овозможува едноставно, 
точно, прецизно и брзо определување на нитисинон во фармацевтски препарати.  
Предностите на овој метод се: едноставна подготовка на примерокот, добра 
прецизност (RSD ≤ 2%) и добар аналитички принос (≥  99%). Предложениот метод 
може да се препорача за рутинска анализа во лабораториите за контрола на квалитет 
на лекови, во студии за стабилност, како и за испитување на потенцијално 
фалсификувани препарати кои содржат нитисинон. 
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Table 1. Results of system suitability test 
Parameter Results Parameter Limit 
RSD of retention time 0.30% < 1% 
RSD of peak area 0.38% < 1% 
Capacity factor k’ 2.30 > 2 
Tailing factor T 0.96 < 2 
Theoretical plate 7613.25 > 2000 
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Table 2. Characteristics of the linear regression analysis 
Parameter NTBC APIª 
Linearity range (μg/mL) 8.44 – 42.2 
Slope 15165 
Intercept -23.019 
Determination coefficient (r2) 0,9999 
SEᵇ of the intercept 11.392 
SE of the slope 52.839 
P-value of the slope 0,099 
ªMean value of 3 determinations 
ᵇSE – Standard error 
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Table 3. Precision of the method 
Precision Parameter % of declared 
content (X) 
RSD (%) Bias (%) 
 
Intra-assay Precision a 
5 mg capsule 106.63  0.29 6.63 
10 mg capsule 107.33  0.50 7.25 
Intermediate Precision a, b 
Day 1 106.63  0.29 6.63 
Day 2 105.20  0.74 5.20 
Day 3 104.77  0.26 4.77 
𝑋 105.53  0.43 5.53 
a n = 6 
b Only 5 mg capsules were tested in Intermediate Precision 
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Table 4. Accuracy of the method 
Theoretical 
amount  
(µg/mL) 
Amount found 
(µg/mL) 
Recovery 
(%) 
Bias 
(%) Mean Recovery ± RSD (%) a  
  81.76 98.98 - 1.02   
82.62 81.13 98.23 - 1.77 98,42 ± 0,49 
  81 98.06 - 1.94   
  106.95 98.59 - 1.41   
108.48 106.6 98.27 - 1.73 98,47 ± 0,17 
  106.91 98.55 - 1.45   
 
124.1 102.21 2,21   
121.41   119.71 98.6 - 1.40  100,76 ± 1,91 
  123.2 101.48 1.48   
 𝑋 99.22 - 0.78 99,22 ± 0,86 
a n = 3 determinations 
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Fig. 1. Structure of nitisinone (accessed from https://www.picswe.com/pics/  hereditary-
tyrosinemia-c7.htmL) 
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Fig. 2. UV spectra of: nitisinone standard solution (1); sample solution of Nitisinone 
capsule 5 mg (2); sample solution of Nitisinone capsule 10 mg (3). 
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Fig. 3. Typical chromatograms of: nitisinone standard solution (a); Nitisinone capsule 5 mg 
sample solution (b); Nitisinone capsule 10 mg sample solution (c); blank solution (d) 
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